Related Experiment Video
Updated: Feb 16, 2026

Platelet-Rich Plasma Lysate for Treatment of Eye Surface Diseases
Published on: August 2, 2022
Platelet-rich plasma-derived scaffolds increase the benefit of delayed mesenchymal stromal cell therapy after severe
Celia Bonilla Horcajo1, Mercedes Zurita Castillo1, Jesús Vaquero Crespo1
1Neuroscience Research Unit and Service of Neurosurgery, Puerta de Hierro Hospital, Majadahonda, Madrid, Spain.
Background:
Cell therapy using mesenchymal stromal cells (MSCs) offers new perspectives in the treatment of traumatic brain injury (TBI). The aim of the present study was to assess the impact of platelet-rich plasma scaffolds (PRPS) as support of MSCs in a delayed phase after severe TBI in rats.
Methods:
TBI was produced by weight-drop impact to the right cerebral hemisphere. Two months after TBI, four experimental groups were established; saline, PRPS, MSCs in saline, or MSCs in PRPS was transplanted into the area of brain lesion through a small hole. All groups were evaluated in the course of the following 12 months after therapy and the animals were then humanely killed.
Results:
Our results showed that a greater functional improvement was obtained after the administration of MSCs in PRPS compared with the other experimental groups.
Discussion:
PRPS enhanced the benefit of cell therapy with MSCs to treat chronic brain damage in rats that suffered a severe TBI. The present findings suggest that the use of intralesional MSCs supported in PRPS may be a strategy of tissue engineering for patients with established neurological severe dysfunction after a TBI.
Related Concept Videos
Benefits of Self-Esteem
Mesenchymal Stem Cells
Increasing Function
Protein Buffers in Blood Plasma and Cells
Certain amino acids can exist in a zwitterion state at a...
Gene Therapy
Traumatic Memory

